Long-range chromatin interactions drive mutant TERT promoter activation

Cancer Discovery

Volumn 6, Issue 11, 2016, Pages 1276-1292

  Akıncılar, Semih Can ^a,b   Khattar, Ekta ^a   Boon, Priscilla Li Shan ^c   Unal, Bilal ^a,b   Fullwood, Melissa Jane ^c   Tergaonkar, Vinay ^a,b,d  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GA BINDING PROTEIN; GENOMIC DNA; HISTONE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR ETS 1; TUMOR PROMOTER; CHROMATIN; TELOMERASE; TERT PROTEIN, HUMAN;

ARTICLE; CHROMATIN CONDENSATION; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME ANALYSIS; COLONY FORMATION; CRISPR CAS SYSTEM; DNA SEQUENCE; EPIGENETICS; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MELANOMA; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN BINDING; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA SEQUENCE; TELOMERASE REVERSE TRANSCRIPTASE GENE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; UPREGULATION; CHROMATIN; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASMS; PROMOTER REGIONS, GENETIC; TELOMERASE; TRANSCRIPTIONAL ACTIVATION;

EID: 84995407566     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0177     Document Type: Article

References (42)

1. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 1988; 85: 6622-6.
2. Blackburn EH. The end of the (DNA) line. Nat Struct Biol 2000; 7: 847-50.
3. O’Sullivan RJ, Karlseder J. Telomeres: Protecting chromosomes against genome instability. Nat Rev Mol Cell Biol 2010; 11: 171-81.
4. Yi X, Shay JW, Wright WE. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res 2001; 29: 4818-25.
5. Shay JW, Wright WE. Senescence and immortalization: Role of telomeres and telomerase. Carcinogenesis 2005; 26: 867-74.
6. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339: 959-61.
7. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339: 957-9.
8. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013; 110: 6021-6.
9. Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, Traves V, et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun 2014; 5: 3401.
10. Akincilar SC, Unal B, Tergaonkar V. Reactivation of telomerase in cancer. Cell Mol Life Sci 2016; 73: 1659-70.
11. Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan R P, et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 2015; 348: 1036-9.
12. Sui X, Kong N, Wang Z, Pan H. Epigenetic regulation of the human telomerase reverse transciptase gene: A potential therapeutic target for the treatment of leukemia (Review). Oncol Lett 2013; 6: 317-22.
13. Stern JL, Theodorescu D, Vogelstein B, Papadopoulos N, Cech TR. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev 2015; 29: 2219-24.
14. Hollenhorst PC, McIntosh LP, Graves BJ. Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 2011; 80: 437-71.
15. Skalicky JJ, Donaldson LW, Petersen JM, Graves BJ, McIntosh LP. Structural coupling of the inhibitory regions flanking the ETS domain of murine Ets-1. Protein Sci 1996; 5: 296-309.
16. Cowley DO, Graves BJ. Phosphorylation represses Ets-1 DNA binding by reinforcing autoinhibition. Genes Dev 2000; 14: 366-76.
17. Chinenov Y, Henzl M, Martin ME. The alpha and beta subunits of the GA-binding protein form a stable heterodimer in solution. Revised model of heterotetrameric complex assembly. J Biol Chem 2000; 275: 7749-56.
18. Li Y, Zhou QL, Sun W, Chandrasekharan P, Cheng HS, Ying Z, et al. Non-canonical NF-kappaB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat Cell Biol 2015; 17: 1327-38.
19. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013; 4: 2218.
20. Barutcu AR, Lajoie BR, McCord RP, Tye CE, Hong D, Messier T L, et al. Chromatin interaction analysis reveals changes in small chromosome and telomere clustering between epithelial and breast cancer cells. Genome Biol 2015; 16: 214.
21. Zhao Z, Tavoosidana G, Sjolinder M, Gondor A, Mariano P, Wang S, et al. Circular chromosome conformation capture (4C) uncovers extensive networks of epigenetically regulated intra-and interchromosomal interactions. Nat Genet 2006; 38: 1341-7.
22. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995; 14: 4240-8.
23. Mathelier A, Fornes O, Arenillas DJ, Chen CY, Denay G, Lee J, et al. JASPAR 2016: A major expansion and update of the open-access database of transcription factor binding profiles. Nucleic Acids Res 2016; 44: D110-5.
24. Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci USA 2003; 100: 8758-63.
25. Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci USA 2014; 111: E2721-30.
26. Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM, Hockemeyer D. Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife 2015; 4.
27. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun 2013; 4: 2185.
28. Bell RJ, Rube HT, Xavier-Magalhaes A, Costa BM, Mancini A, Song JS, et al. Understanding TERT Promoter Mutations: A common path to immortality. Mol Cancer Res 2016; 14: 315-23.
29. Palumbo SL, Ebbinghaus SW, Hurley LH. Formation of a unique endto-end stacked pair of G-quadruplexes in the hTERT core promoter with implications for inhibition of telomerase by G-quadruplex interactive ligands. J Am Chem Soc 2009; 131: 10878-91.
30. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013; 8: 2281-308.
31. Koh CM, Khattar E, Leow SC, Liu CY, Muller J, Ang WX, et al. Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. J Clin Invest 2015; 125: 2109-22.
32. Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD, et al. Telomerase directly regulates NF-kappaB-dependent transcription. Nat Cell Biol 2012; 14: 1270-81.
33. Zhao Y, Cheng D, Wang S, Zhu J. Dual roles of c-Myc in the regulation of hTERT gene. Nucleic Acids Res 2014; 42: 10385-98.
34. Splinter E, de Wit E, van de Werken HJ, Klous P, de Laat W. Determining long-range chromatin interactions for selected genomic sites using 4C-seq technology: from fixation to computation. Methods 2012; 58: 221-30.
35. Andrews S. FastQC: A quality control tool for high throughput sequence data 2010. Available from: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/. Date accessed: October 26, 2015.
36. Buffalo V. Scythe 2012. Available from: https://github.com/vsbuffalo/ scythe. Date accessed: October 26, 2015.
37. Lassmann T. TagDust2: A generic method to extract reads from sequencing data. BMC Bioinformatics 2015; 16: 24.
38. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012; 9: 357-9.
39. Thongjuea S, Stadhouders R, Grosveld FG, Soler E, Lenhard B. r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data. Nucleic Acids Res 2013; 41: e132.
40. Klein FA, Pakozdi T, Anders S, Ghavi-Helm Y, Furlong EE, Huber W. FourCSeq: Analysis of 4C sequencing data. Bioinformatics 2015; 31: 3085-91.
41. Hagege H, Klous P, Braem C, Splinter E, Dekker J, Cathala G, et al. Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat Protoc 2007; 2: 1722-33.
42. Akincilar SC, Low KC, Liu CY, Yan TD, Oji A, Ikawa M, et al. Quantitative assessment of telomerase components in cancer cell lines. FEBS Lett 2015; 589: 974-84.